nodes	percent_of_prediction	percent_of_DWPC	metapath
Deferoxamine—XDH—Carboplatin—testicular cancer	0.348	0.412	CbGbCtD
Deferoxamine—XDH—Cisplatin—testicular cancer	0.297	0.352	CbGbCtD
Deferoxamine—XDH—Doxorubicin—testicular cancer	0.199	0.236	CbGbCtD
Deferoxamine—Mediastinal disorder—Etoposide—testicular cancer	0.000318	0.00204	CcSEcCtD
Deferoxamine—Pain—Bleomycin—testicular cancer	0.000317	0.00203	CcSEcCtD
Deferoxamine—Anaphylactic shock—Ifosfamide—testicular cancer	0.000317	0.00203	CcSEcCtD
Deferoxamine—Oedema—Ifosfamide—testicular cancer	0.000317	0.00203	CcSEcCtD
Deferoxamine—Vision blurred—Cisplatin—testicular cancer	0.000316	0.00202	CcSEcCtD
Deferoxamine—Anaphylactoid reaction—Methotrexate—testicular cancer	0.000315	0.00202	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Dactinomycin—testicular cancer	0.000315	0.00202	CcSEcCtD
Deferoxamine—Infection—Ifosfamide—testicular cancer	0.000315	0.00202	CcSEcCtD
Deferoxamine—Nervous system disorder—Ifosfamide—testicular cancer	0.000311	0.00199	CcSEcCtD
Deferoxamine—Thrombocytopenia—Ifosfamide—testicular cancer	0.00031	0.00199	CcSEcCtD
Deferoxamine—Renal failure acute—Epirubicin—testicular cancer	0.000309	0.00198	CcSEcCtD
Deferoxamine—Skin disorder—Ifosfamide—testicular cancer	0.000308	0.00198	CcSEcCtD
Deferoxamine—Vomiting—Chlorambucil—testicular cancer	0.000305	0.00195	CcSEcCtD
Deferoxamine—Hepatic function abnormal—Doxorubicin—testicular cancer	0.000302	0.00194	CcSEcCtD
Deferoxamine—Diarrhoea—Vinblastine—testicular cancer	0.000301	0.00193	CcSEcCtD
Deferoxamine—Renal impairment—Epirubicin—testicular cancer	0.0003	0.00192	CcSEcCtD
Deferoxamine—Leukopenia—Cisplatin—testicular cancer	0.0003	0.00192	CcSEcCtD
Deferoxamine—Hypotension—Ifosfamide—testicular cancer	0.000296	0.0019	CcSEcCtD
Deferoxamine—Pain—Dactinomycin—testicular cancer	0.000296	0.0019	CcSEcCtD
Deferoxamine—Anaphylactoid reaction—Epirubicin—testicular cancer	0.000295	0.00189	CcSEcCtD
Deferoxamine—Muscle spasms—Etoposide—testicular cancer	0.000295	0.00189	CcSEcCtD
Deferoxamine—Urticaria—Bleomycin—testicular cancer	0.000295	0.00189	CcSEcCtD
Deferoxamine—Body temperature increased—Bleomycin—testicular cancer	0.000293	0.00188	CcSEcCtD
Deferoxamine—Dizziness—Vinblastine—testicular cancer	0.000291	0.00186	CcSEcCtD
Deferoxamine—Convulsion—Cisplatin—testicular cancer	0.00029	0.00186	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Ifosfamide—testicular cancer	0.000289	0.00185	CcSEcCtD
Deferoxamine—Renal failure acute—Doxorubicin—testicular cancer	0.000286	0.00184	CcSEcCtD
Deferoxamine—Myalgia—Cisplatin—testicular cancer	0.000285	0.00183	CcSEcCtD
Deferoxamine—Nausea—Chlorambucil—testicular cancer	0.000285	0.00183	CcSEcCtD
Deferoxamine—Paraesthesia—Ifosfamide—testicular cancer	0.000285	0.00183	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—testicular cancer	0.000283	0.00182	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Dactinomycin—testicular cancer	0.000283	0.00181	CcSEcCtD
Deferoxamine—Dyspnoea—Ifosfamide—testicular cancer	0.000283	0.00181	CcSEcCtD
Deferoxamine—Vomiting—Vinblastine—testicular cancer	0.000279	0.00179	CcSEcCtD
Deferoxamine—Renal impairment—Doxorubicin—testicular cancer	0.000278	0.00178	CcSEcCtD
Deferoxamine—Headache—Vinblastine—testicular cancer	0.000275	0.00177	CcSEcCtD
Deferoxamine—Leukopenia—Etoposide—testicular cancer	0.000275	0.00176	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Ifosfamide—testicular cancer	0.000274	0.00176	CcSEcCtD
Deferoxamine—Abdominal pain—Dactinomycin—testicular cancer	0.000274	0.00175	CcSEcCtD
Deferoxamine—Body temperature increased—Dactinomycin—testicular cancer	0.000274	0.00175	CcSEcCtD
Deferoxamine—Oedema—Cisplatin—testicular cancer	0.000273	0.00175	CcSEcCtD
Deferoxamine—Anaphylactic shock—Cisplatin—testicular cancer	0.000273	0.00175	CcSEcCtD
Deferoxamine—Hypersensitivity—Bleomycin—testicular cancer	0.000273	0.00175	CcSEcCtD
Deferoxamine—Anaphylactoid reaction—Doxorubicin—testicular cancer	0.000273	0.00175	CcSEcCtD
Deferoxamine—Infection—Cisplatin—testicular cancer	0.000272	0.00174	CcSEcCtD
Deferoxamine—Pain—Ifosfamide—testicular cancer	0.000271	0.00174	CcSEcCtD
Deferoxamine—Nervous system disorder—Cisplatin—testicular cancer	0.000268	0.00172	CcSEcCtD
Deferoxamine—Thrombocytopenia—Cisplatin—testicular cancer	0.000268	0.00172	CcSEcCtD
Deferoxamine—Blood creatinine increased—Epirubicin—testicular cancer	0.000268	0.00172	CcSEcCtD
Deferoxamine—Tachycardia—Cisplatin—testicular cancer	0.000267	0.00171	CcSEcCtD
Deferoxamine—Convulsion—Etoposide—testicular cancer	0.000266	0.00171	CcSEcCtD
Deferoxamine—Skin disorder—Cisplatin—testicular cancer	0.000266	0.0017	CcSEcCtD
Deferoxamine—Asthma—Methotrexate—testicular cancer	0.000264	0.00169	CcSEcCtD
Deferoxamine—Pruritus—Bleomycin—testicular cancer	0.000263	0.00168	CcSEcCtD
Deferoxamine—Eosinophilia—Methotrexate—testicular cancer	0.000261	0.00168	CcSEcCtD
Deferoxamine—Nausea—Vinblastine—testicular cancer	0.000261	0.00167	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—testicular cancer	0.000259	0.00166	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Ifosfamide—testicular cancer	0.000259	0.00166	CcSEcCtD
Deferoxamine—Hypotension—Cisplatin—testicular cancer	0.000255	0.00164	CcSEcCtD
Deferoxamine—Hypersensitivity—Dactinomycin—testicular cancer	0.000255	0.00164	CcSEcCtD
Deferoxamine—Abdominal discomfort—Methotrexate—testicular cancer	0.000253	0.00162	CcSEcCtD
Deferoxamine—Urticaria—Ifosfamide—testicular cancer	0.000252	0.00162	CcSEcCtD
Deferoxamine—Abdominal pain—Ifosfamide—testicular cancer	0.000251	0.00161	CcSEcCtD
Deferoxamine—Body temperature increased—Ifosfamide—testicular cancer	0.000251	0.00161	CcSEcCtD
Deferoxamine—Anaphylactic shock—Etoposide—testicular cancer	0.00025	0.00161	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Cisplatin—testicular cancer	0.000249	0.0016	CcSEcCtD
Deferoxamine—Infection—Etoposide—testicular cancer	0.000249	0.0016	CcSEcCtD
Deferoxamine—Blood creatinine increased—Doxorubicin—testicular cancer	0.000248	0.00159	CcSEcCtD
Deferoxamine—Asthma—Epirubicin—testicular cancer	0.000247	0.00158	CcSEcCtD
Deferoxamine—Dysuria—Methotrexate—testicular cancer	0.000247	0.00158	CcSEcCtD
Deferoxamine—Paraesthesia—Cisplatin—testicular cancer	0.000245	0.00157	CcSEcCtD
Deferoxamine—Thrombocytopenia—Etoposide—testicular cancer	0.000245	0.00157	CcSEcCtD
Deferoxamine—Tachycardia—Etoposide—testicular cancer	0.000244	0.00157	CcSEcCtD
Deferoxamine—Eosinophilia—Epirubicin—testicular cancer	0.000244	0.00157	CcSEcCtD
Deferoxamine—Dyspnoea—Cisplatin—testicular cancer	0.000244	0.00156	CcSEcCtD
Deferoxamine—Skin disorder—Etoposide—testicular cancer	0.000243	0.00156	CcSEcCtD
Deferoxamine—Diarrhoea—Dactinomycin—testicular cancer	0.000237	0.00152	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Cisplatin—testicular cancer	0.000236	0.00151	CcSEcCtD
Deferoxamine—Vomiting—Bleomycin—testicular cancer	0.000236	0.00151	CcSEcCtD
Deferoxamine—Infestation NOS—Methotrexate—testicular cancer	0.000235	0.00151	CcSEcCtD
Deferoxamine—Infestation—Methotrexate—testicular cancer	0.000235	0.00151	CcSEcCtD
Deferoxamine—Hypotension—Etoposide—testicular cancer	0.000234	0.0015	CcSEcCtD
Deferoxamine—Pain—Cisplatin—testicular cancer	0.000234	0.0015	CcSEcCtD
Deferoxamine—Hypersensitivity—Ifosfamide—testicular cancer	0.000234	0.0015	CcSEcCtD
Deferoxamine—Renal failure—Methotrexate—testicular cancer	0.000231	0.00148	CcSEcCtD
Deferoxamine—Dysuria—Epirubicin—testicular cancer	0.000231	0.00148	CcSEcCtD
Deferoxamine—Asthma—Doxorubicin—testicular cancer	0.000228	0.00147	CcSEcCtD
Deferoxamine—Eosinophilia—Doxorubicin—testicular cancer	0.000226	0.00145	CcSEcCtD
Deferoxamine—Paraesthesia—Etoposide—testicular cancer	0.000225	0.00144	CcSEcCtD
Deferoxamine—Pruritus—Ifosfamide—testicular cancer	0.000224	0.00144	CcSEcCtD
Deferoxamine—Dyspnoea—Etoposide—testicular cancer	0.000223	0.00143	CcSEcCtD
Deferoxamine—Nausea—Bleomycin—testicular cancer	0.00022	0.00141	CcSEcCtD
Deferoxamine—Infestation NOS—Epirubicin—testicular cancer	0.00022	0.00141	CcSEcCtD
Deferoxamine—Infestation—Epirubicin—testicular cancer	0.00022	0.00141	CcSEcCtD
Deferoxamine—Vomiting—Dactinomycin—testicular cancer	0.00022	0.00141	CcSEcCtD
Deferoxamine—Diarrhoea—Ifosfamide—testicular cancer	0.000217	0.00139	CcSEcCtD
Deferoxamine—Renal failure—Epirubicin—testicular cancer	0.000216	0.00139	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Etoposide—testicular cancer	0.000216	0.00139	CcSEcCtD
Deferoxamine—Body temperature increased—Cisplatin—testicular cancer	0.000216	0.00139	CcSEcCtD
Deferoxamine—Neuropathy peripheral—Epirubicin—testicular cancer	0.000216	0.00138	CcSEcCtD
Deferoxamine—Pain—Etoposide—testicular cancer	0.000214	0.00137	CcSEcCtD
Deferoxamine—Dysuria—Doxorubicin—testicular cancer	0.000214	0.00137	CcSEcCtD
Deferoxamine—Dizziness—Ifosfamide—testicular cancer	0.00021	0.00134	CcSEcCtD
Deferoxamine—Urinary tract disorder—Methotrexate—testicular cancer	0.000209	0.00134	CcSEcCtD
Deferoxamine—Urethral disorder—Methotrexate—testicular cancer	0.000207	0.00133	CcSEcCtD
Deferoxamine—Nausea—Dactinomycin—testicular cancer	0.000206	0.00132	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Etoposide—testicular cancer	0.000205	0.00131	CcSEcCtD
Deferoxamine—Infestation NOS—Doxorubicin—testicular cancer	0.000204	0.00131	CcSEcCtD
Deferoxamine—Infestation—Doxorubicin—testicular cancer	0.000204	0.00131	CcSEcCtD
Deferoxamine—Visual impairment—Methotrexate—testicular cancer	0.000203	0.00131	CcSEcCtD
Deferoxamine—Vomiting—Ifosfamide—testicular cancer	0.000202	0.00129	CcSEcCtD
Deferoxamine—Hypersensitivity—Cisplatin—testicular cancer	0.000201	0.00129	CcSEcCtD
Deferoxamine—Bradycardia—Epirubicin—testicular cancer	0.000201	0.00129	CcSEcCtD
Deferoxamine—Renal failure—Doxorubicin—testicular cancer	0.0002	0.00128	CcSEcCtD
Deferoxamine—Neuropathy peripheral—Doxorubicin—testicular cancer	0.0002	0.00128	CcSEcCtD
Deferoxamine—Urticaria—Etoposide—testicular cancer	0.000199	0.00128	CcSEcCtD
Deferoxamine—Abdominal pain—Etoposide—testicular cancer	0.000198	0.00127	CcSEcCtD
Deferoxamine—Body temperature increased—Etoposide—testicular cancer	0.000198	0.00127	CcSEcCtD
Deferoxamine—Eye disorder—Methotrexate—testicular cancer	0.000197	0.00127	CcSEcCtD
Deferoxamine—Tinnitus—Methotrexate—testicular cancer	0.000197	0.00126	CcSEcCtD
Deferoxamine—Urinary tract disorder—Epirubicin—testicular cancer	0.000195	0.00125	CcSEcCtD
Deferoxamine—Connective tissue disorder—Epirubicin—testicular cancer	0.000194	0.00125	CcSEcCtD
Deferoxamine—Urethral disorder—Epirubicin—testicular cancer	0.000194	0.00124	CcSEcCtD
Deferoxamine—Angiopathy—Methotrexate—testicular cancer	0.000192	0.00123	CcSEcCtD
Deferoxamine—Immune system disorder—Methotrexate—testicular cancer	0.000191	0.00122	CcSEcCtD
Deferoxamine—Visual impairment—Epirubicin—testicular cancer	0.00019	0.00122	CcSEcCtD
Deferoxamine—Mediastinal disorder—Methotrexate—testicular cancer	0.00019	0.00122	CcSEcCtD
Deferoxamine—Nausea—Ifosfamide—testicular cancer	0.000188	0.00121	CcSEcCtD
Deferoxamine—Diarrhoea—Cisplatin—testicular cancer	0.000187	0.0012	CcSEcCtD
Deferoxamine—Bradycardia—Doxorubicin—testicular cancer	0.000186	0.00119	CcSEcCtD
Deferoxamine—Eye disorder—Epirubicin—testicular cancer	0.000185	0.00118	CcSEcCtD
Deferoxamine—Hypersensitivity—Etoposide—testicular cancer	0.000185	0.00118	CcSEcCtD
Deferoxamine—Tinnitus—Epirubicin—testicular cancer	0.000184	0.00118	CcSEcCtD
Deferoxamine—Erythema—Methotrexate—testicular cancer	0.000184	0.00118	CcSEcCtD
Deferoxamine—Urinary tract disorder—Doxorubicin—testicular cancer	0.000181	0.00116	CcSEcCtD
Deferoxamine—Connective tissue disorder—Doxorubicin—testicular cancer	0.00018	0.00115	CcSEcCtD
Deferoxamine—Angiopathy—Epirubicin—testicular cancer	0.000179	0.00115	CcSEcCtD
Deferoxamine—Urethral disorder—Doxorubicin—testicular cancer	0.000179	0.00115	CcSEcCtD
Deferoxamine—Immune system disorder—Epirubicin—testicular cancer	0.000178	0.00114	CcSEcCtD
Deferoxamine—Mediastinal disorder—Epirubicin—testicular cancer	0.000178	0.00114	CcSEcCtD
Deferoxamine—Pruritus—Etoposide—testicular cancer	0.000177	0.00114	CcSEcCtD
Deferoxamine—Arrhythmia—Epirubicin—testicular cancer	0.000177	0.00113	CcSEcCtD
Deferoxamine—Visual impairment—Doxorubicin—testicular cancer	0.000176	0.00113	CcSEcCtD
Deferoxamine—Vomiting—Cisplatin—testicular cancer	0.000174	0.00111	CcSEcCtD
Deferoxamine—Vision blurred—Methotrexate—testicular cancer	0.000173	0.00111	CcSEcCtD
Deferoxamine—Erythema—Epirubicin—testicular cancer	0.000172	0.0011	CcSEcCtD
Deferoxamine—Diarrhoea—Etoposide—testicular cancer	0.000171	0.0011	CcSEcCtD
Deferoxamine—Eye disorder—Doxorubicin—testicular cancer	0.000171	0.0011	CcSEcCtD
Deferoxamine—Tinnitus—Doxorubicin—testicular cancer	0.00017	0.00109	CcSEcCtD
Deferoxamine—Angiopathy—Doxorubicin—testicular cancer	0.000166	0.00106	CcSEcCtD
Deferoxamine—Dizziness—Etoposide—testicular cancer	0.000166	0.00106	CcSEcCtD
Deferoxamine—Muscle spasms—Epirubicin—testicular cancer	0.000165	0.00106	CcSEcCtD
Deferoxamine—Immune system disorder—Doxorubicin—testicular cancer	0.000165	0.00106	CcSEcCtD
Deferoxamine—Mediastinal disorder—Doxorubicin—testicular cancer	0.000165	0.00106	CcSEcCtD
Deferoxamine—Leukopenia—Methotrexate—testicular cancer	0.000165	0.00106	CcSEcCtD
Deferoxamine—Arrhythmia—Doxorubicin—testicular cancer	0.000163	0.00105	CcSEcCtD
Deferoxamine—Nausea—Cisplatin—testicular cancer	0.000162	0.00104	CcSEcCtD
Deferoxamine—Vision blurred—Epirubicin—testicular cancer	0.000162	0.00104	CcSEcCtD
Deferoxamine—Convulsion—Methotrexate—testicular cancer	0.000159	0.00102	CcSEcCtD
Deferoxamine—Vomiting—Etoposide—testicular cancer	0.000159	0.00102	CcSEcCtD
Deferoxamine—Erythema—Doxorubicin—testicular cancer	0.000159	0.00102	CcSEcCtD
Deferoxamine—Headache—Etoposide—testicular cancer	0.000157	0.00101	CcSEcCtD
Deferoxamine—Myalgia—Methotrexate—testicular cancer	0.000156	0.001	CcSEcCtD
Deferoxamine—Arthralgia—Methotrexate—testicular cancer	0.000156	0.001	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.000155	0.000997	CcSEcCtD
Deferoxamine—Leukopenia—Epirubicin—testicular cancer	0.000154	0.000988	CcSEcCtD
Deferoxamine—Muscle spasms—Doxorubicin—testicular cancer	0.000153	0.000981	CcSEcCtD
Deferoxamine—Anaphylactic shock—Methotrexate—testicular cancer	0.00015	0.000962	CcSEcCtD
Deferoxamine—Vision blurred—Doxorubicin—testicular cancer	0.00015	0.000962	CcSEcCtD
Deferoxamine—Convulsion—Epirubicin—testicular cancer	0.000149	0.000956	CcSEcCtD
Deferoxamine—Infection—Methotrexate—testicular cancer	0.000149	0.000956	CcSEcCtD
Deferoxamine—Nausea—Etoposide—testicular cancer	0.000149	0.000954	CcSEcCtD
Deferoxamine—Nervous system disorder—Methotrexate—testicular cancer	0.000147	0.000944	CcSEcCtD
Deferoxamine—Thrombocytopenia—Methotrexate—testicular cancer	0.000147	0.000942	CcSEcCtD
Deferoxamine—Myalgia—Epirubicin—testicular cancer	0.000146	0.000939	CcSEcCtD
Deferoxamine—Arthralgia—Epirubicin—testicular cancer	0.000146	0.000939	CcSEcCtD
Deferoxamine—Skin disorder—Methotrexate—testicular cancer	0.000146	0.000935	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.000145	0.000933	CcSEcCtD
Deferoxamine—Leukopenia—Doxorubicin—testicular cancer	0.000142	0.000914	CcSEcCtD
Deferoxamine—Anaphylactic shock—Epirubicin—testicular cancer	0.00014	0.0009	CcSEcCtD
Deferoxamine—Oedema—Epirubicin—testicular cancer	0.00014	0.0009	CcSEcCtD
Deferoxamine—Hypotension—Methotrexate—testicular cancer	0.00014	0.000899	CcSEcCtD
Deferoxamine—Infection—Epirubicin—testicular cancer	0.000139	0.000894	CcSEcCtD
Deferoxamine—Shock—Epirubicin—testicular cancer	0.000138	0.000886	CcSEcCtD
Deferoxamine—Convulsion—Doxorubicin—testicular cancer	0.000138	0.000884	CcSEcCtD
Deferoxamine—Nervous system disorder—Epirubicin—testicular cancer	0.000138	0.000883	CcSEcCtD
Deferoxamine—Thrombocytopenia—Epirubicin—testicular cancer	0.000137	0.000882	CcSEcCtD
Deferoxamine—Tachycardia—Epirubicin—testicular cancer	0.000137	0.000879	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Methotrexate—testicular cancer	0.000137	0.000877	CcSEcCtD
Deferoxamine—Skin disorder—Epirubicin—testicular cancer	0.000136	0.000875	CcSEcCtD
Deferoxamine—Arthralgia—Doxorubicin—testicular cancer	0.000136	0.000869	CcSEcCtD
Deferoxamine—Myalgia—Doxorubicin—testicular cancer	0.000136	0.000869	CcSEcCtD
Deferoxamine—Paraesthesia—Methotrexate—testicular cancer	0.000135	0.000864	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.000135	0.000863	CcSEcCtD
Deferoxamine—Dyspnoea—Methotrexate—testicular cancer	0.000134	0.000858	CcSEcCtD
Deferoxamine—Hypotension—Epirubicin—testicular cancer	0.000131	0.000841	CcSEcCtD
Deferoxamine—Oedema—Doxorubicin—testicular cancer	0.00013	0.000833	CcSEcCtD
Deferoxamine—Anaphylactic shock—Doxorubicin—testicular cancer	0.00013	0.000833	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Methotrexate—testicular cancer	0.00013	0.000831	CcSEcCtD
Deferoxamine—Infection—Doxorubicin—testicular cancer	0.000129	0.000828	CcSEcCtD
Deferoxamine—Pain—Methotrexate—testicular cancer	0.000128	0.000823	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Epirubicin—testicular cancer	0.000128	0.00082	CcSEcCtD
Deferoxamine—Shock—Doxorubicin—testicular cancer	0.000128	0.00082	CcSEcCtD
Deferoxamine—Nervous system disorder—Doxorubicin—testicular cancer	0.000127	0.000817	CcSEcCtD
Deferoxamine—Thrombocytopenia—Doxorubicin—testicular cancer	0.000127	0.000816	CcSEcCtD
Deferoxamine—Tachycardia—Doxorubicin—testicular cancer	0.000127	0.000813	CcSEcCtD
Deferoxamine—Skin disorder—Doxorubicin—testicular cancer	0.000126	0.000809	CcSEcCtD
Deferoxamine—Paraesthesia—Epirubicin—testicular cancer	0.000126	0.000808	CcSEcCtD
Deferoxamine—Dyspnoea—Epirubicin—testicular cancer	0.000125	0.000803	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Methotrexate—testicular cancer	0.000123	0.000787	CcSEcCtD
Deferoxamine—Hypotension—Doxorubicin—testicular cancer	0.000121	0.000778	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000121	0.000777	CcSEcCtD
Deferoxamine—Pain—Epirubicin—testicular cancer	0.00012	0.00077	CcSEcCtD
Deferoxamine—Urticaria—Methotrexate—testicular cancer	0.000119	0.000764	CcSEcCtD
Deferoxamine—Body temperature increased—Methotrexate—testicular cancer	0.000119	0.000761	CcSEcCtD
Deferoxamine—Abdominal pain—Methotrexate—testicular cancer	0.000119	0.000761	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Doxorubicin—testicular cancer	0.000118	0.000759	CcSEcCtD
Deferoxamine—Paraesthesia—Doxorubicin—testicular cancer	0.000117	0.000748	CcSEcCtD
Deferoxamine—Dyspnoea—Doxorubicin—testicular cancer	0.000116	0.000743	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Epirubicin—testicular cancer	0.000115	0.000736	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000112	0.000719	CcSEcCtD
Deferoxamine—Urticaria—Epirubicin—testicular cancer	0.000112	0.000715	CcSEcCtD
Deferoxamine—Pain—Doxorubicin—testicular cancer	0.000111	0.000712	CcSEcCtD
Deferoxamine—Abdominal pain—Epirubicin—testicular cancer	0.000111	0.000712	CcSEcCtD
Deferoxamine—Body temperature increased—Epirubicin—testicular cancer	0.000111	0.000712	CcSEcCtD
Deferoxamine—Hypersensitivity—Methotrexate—testicular cancer	0.000111	0.000709	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Doxorubicin—testicular cancer	0.000106	0.000681	CcSEcCtD
Deferoxamine—Pruritus—Methotrexate—testicular cancer	0.000106	0.000681	CcSEcCtD
Deferoxamine—Hypersensitivity—Epirubicin—testicular cancer	0.000103	0.000663	CcSEcCtD
Deferoxamine—Urticaria—Doxorubicin—testicular cancer	0.000103	0.000662	CcSEcCtD
Deferoxamine—Body temperature increased—Doxorubicin—testicular cancer	0.000103	0.000659	CcSEcCtD
Deferoxamine—Abdominal pain—Doxorubicin—testicular cancer	0.000103	0.000659	CcSEcCtD
Deferoxamine—Diarrhoea—Methotrexate—testicular cancer	0.000103	0.000658	CcSEcCtD
Deferoxamine—Pruritus—Epirubicin—testicular cancer	9.93e-05	0.000637	CcSEcCtD
Deferoxamine—Dizziness—Methotrexate—testicular cancer	9.92e-05	0.000636	CcSEcCtD
Deferoxamine—Diarrhoea—Epirubicin—testicular cancer	9.61e-05	0.000616	CcSEcCtD
Deferoxamine—Hypersensitivity—Doxorubicin—testicular cancer	9.57e-05	0.000614	CcSEcCtD
Deferoxamine—Vomiting—Methotrexate—testicular cancer	9.54e-05	0.000612	CcSEcCtD
Deferoxamine—Headache—Methotrexate—testicular cancer	9.4e-05	0.000603	CcSEcCtD
Deferoxamine—Dizziness—Epirubicin—testicular cancer	9.28e-05	0.000595	CcSEcCtD
Deferoxamine—Pruritus—Doxorubicin—testicular cancer	9.19e-05	0.000589	CcSEcCtD
Deferoxamine—Vomiting—Epirubicin—testicular cancer	8.93e-05	0.000572	CcSEcCtD
Deferoxamine—Nausea—Methotrexate—testicular cancer	8.91e-05	0.000571	CcSEcCtD
Deferoxamine—Diarrhoea—Doxorubicin—testicular cancer	8.89e-05	0.00057	CcSEcCtD
Deferoxamine—Headache—Epirubicin—testicular cancer	8.79e-05	0.000564	CcSEcCtD
Deferoxamine—Dizziness—Doxorubicin—testicular cancer	8.59e-05	0.000551	CcSEcCtD
Deferoxamine—Nausea—Epirubicin—testicular cancer	8.34e-05	0.000535	CcSEcCtD
Deferoxamine—Vomiting—Doxorubicin—testicular cancer	8.26e-05	0.00053	CcSEcCtD
Deferoxamine—Headache—Doxorubicin—testicular cancer	8.14e-05	0.000522	CcSEcCtD
Deferoxamine—Nausea—Doxorubicin—testicular cancer	7.72e-05	0.000495	CcSEcCtD
